Endometrial Cancers Harboring Mutated Fibroblast Growth Factor Receptor 2 Protein Are Successfully Treated With a New Small Tyrosine Kinase Inhibitor in an Orthotopic Mouse Model

OBJECTIVES: AL3818 (anlotinib) is a receptor tyrosine kinase inhibitor targeting vascular endothelial growth factor receptors (VEGFR1, VEGFR2/KDR, and VEGFR3), stem cell factor receptor (C-kit), platelet-derived growth factor (PDGFβ), and fibroblast growth factor receptors (FGFR1, FGFR2, and FGFR3)....

Descripción completa

Detalles Bibliográficos
Autores principales: Taurin, Sebastien, Yang, Chieh-Hsiang, Reyes, Maria, Cho, Sungpil, Coombs, Demetrius M., Jarboe, Elke A., Werner, Theresa L., Peterson, C. Matthew, Janát-Amsbury, Margit M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2018
Materias:
Uterine Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5735020/
https://www.ncbi.nlm.nih.gov/pubmed/28953502
http://dx.doi.org/10.1097/IGC.0000000000001129

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5735020/
https://www.ncbi.nlm.nih.gov/pubmed/28953502
http://dx.doi.org/10.1097/IGC.0000000000001129

Ejemplares similares